日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance

靶向特定细胞周期节点可克服KRAS/RAS抑制剂耐药性。

Kumarasamy, Vishnu; Wang, Jianxin; Yau, Edwin; Abel, Ethan V; Witkiewicz, Agnieszka K; Knudsen, Erik S

Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma.

靶向 FGFR4 可消除 HNF1A 驱动的胰腺导管腺癌转移

Crawford Katherine J, Humphrey Kennedy S, Cortes Eduardo, Wang Jianxin, Kumarasamy Vishnu, Wan Yin, Long Mark D, Feigin Michael E, Witkiewicz Agnieszka K, Mann Karen M, Knudsen Erik S, Abel Ethan V

Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222.

肿瘤抑制因子对选择性 CDK2 抑制剂 BLU-222 的反应存在差异

Dommer Adam P, Kumarasamy Vishnu, Wang Jianxin, O'Connor Thomas N, Roti Michelle, Mahan Sidney, McLean Karen, Knudsen Erik S, Witkiewicz Agnieszka K

Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer.

内在的 RB 激活诱导肿瘤和基质抗肿瘤反应,从而限制三阴性乳腺癌。

Wan Yin, Wang Jianxin, O'Connor Thomas N, Kumarasamy Vishnu, Sanidas Ioannis, Abrams Scott I, Witkiewicz Agnieszka K, Knudsen Erik S

RB loss sensitizes triple-negative breast cancer to apoptosis induced by cellular stress

RB缺失使三阴性乳腺癌对细胞应激诱导的细胞凋亡更加敏感。

Witkiewicz, Agnieszka K; Kaligotla Venkata, Subrahmanya Anirudh; Knudsen, Erik S; Kumarasamy, Vishnu

Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy

癌细胞周期失调:异质性、可塑性和治疗

Witkiewicz, Agnieszka K; Kumarasamy, Vishnu; Sanidas, Ioannis; Knudsen, Erik S

Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows

化疗与 CDK4/6 抑制剂:意想不到的合作伙伴

Roberts, Patrick J; Kumarasamy, Vishnu; Witkiewicz, Agnieszka K; Knudsen, Erik S

Synthesis of Constrained Heterocycles Employing Two Post-Ugi Cyclization Methods for Rapid Library Generation with In Cellulo Activity

利用两种后Ugi环化方法合成具有细胞内活性的受限杂环化合物,实现快速构建化合物库。

McConnell, Nicholas; Xu, Zhigang; Kumarasamy, Vishnu; Sun, Daekyu; Frett, Brendan; Li, Hong-Yu